Antibiotic management of febrile neutropenia: Current developments and future directions

Journal of Chemotherapy

Volumn 22, Issue 1, 2010, Pages 5-12

  Mebis, J ^a,b   Goossens, H ^a   Berneman, Z N ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Medical Oncology   (Belgium)

Author keywords

Febrile; Gram negative bacteria; Neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; ICLAPRIM; LEVOFLOXACIN; LIPOPEPTIDE; MEROPENEM; MONOCLONAL ANTIBODY; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RISK; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; MULTIPLE MYELOMA; NEPHROTOXICITY; PSEUDOMONAS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STAPHYLOCOCCUS; STREPTOCOCCUS; SUPERINFECTION; T CELL LYMPHOMA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 77950162473     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.1.5     Document Type: Review

References (76)

1. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103(6):1103-13.
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64(2):328-40.
3. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145(9):1621-9.
4. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284(19):1061-5.
5. Leibovici L, Paul M, Cullen M. Bucaneve G, Gafter-Guili A. Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107(8):1743-51.
6. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993;328(18):1323-32.
7. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77(5):707-14.
8. Klastersky J. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 19971. Rev Med Brux 1997;18(5):323-7.
9. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998:16(3):1179-87.
10. Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36(2):149-58.
11. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001;33(7):947-53.
12. Fainstein V, Elting LS, Bodey GP. Bacteremia caused by non-sporulating anaerobes in cancer patients. A 12-year experience. Medicine (Baltimore) 1989;68(3):151-62.
13. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27(20):3398-409.
14. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116(2):475-82.
15. Walsh TJ, Groll AH. Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs 2001;2(10):1366-7.
16. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005;52(1):15-20.
17. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology. diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006:162(1):1-15.
18. Cornely OA. Aspergillus to Zygomycates: causes. risk factors, prevention, and treatment of invasive fungal infections. Infection 2008;36(4):296-313.
19. Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV, Jonas RN. Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemothar 1999;43(4):940-3.
20. et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer 2008; 16(9): 1085-8.
21. Maschmeyer G, Haas A. The epidemiology and treatment of infections in cencar patients. Int J Antimicrob Agents 2008:31(3):193-7.
22. Tunkel AR, Sepkowitz KA. Infections causad by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34(ll):1524-9.
23. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36(9):1103-10.
24. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40 Suppl 4:S246-S252.
25. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection. J Infect Control 2006;34(8):534-6
26. Matar MJ, Safdar A, Rolston KV. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin Infect Dis 2006;42(10):1506-7.
27. in cancer patients. Bone Marrow Transplant 2007;39(9):567-8.
28. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61(3):721-8.
29. von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58(4):891-4.
30. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003;36(8):1006-12.
31. Mebis J, Goossens H, Bruyneel P, Sion JP, Meeus I, Van DJ, et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998:12(10):1627-9.
32. Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, et al. in the treatment of patients with advanced follicular lymphoma. Cancer 2009;115(9):1906-13.
33. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009;88(2):121-32.
34. Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008;8(4):237-40.
35. Ramzi J, Mohamed Z, Yosr B, Karima K, Raihane B, Lamia A, et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology 2007;12(6):543-8.
36. Engel A, Knoll S, Kern P, Kern WV. Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications. Infection 2005;33(5-6):380-2.
37. of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008;36(5):396-407.
38. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10(2):316-22.
39. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(6):3038-51.
40. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 Suppl 1:S51-S59.
41. de Souza V, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC. Performance of a modified MASCC index score far identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2008;16(7):841-6.
42. Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009;20(3):513-9.
43. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328(7441):668.
44. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-51.
45. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005;(3):CD003914.
46. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991;163(5):951-8.
47. Kern WV, Cometta A, De BR, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341(5):312-8.
48. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341(5):305-11.
49. Rolston KV, Manzullo EF, Elting LS, Frisbee Huma SE, McMahon L, low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 2006;106(11):2489-94.
50. Marra CA, Frighetto L, Quaia CB, de Lemos ML, Warkentin DI, Marra F, et al. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 200;20(8):931-40
51. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodriques I, Geoffrois L, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008;16(9):1017-23
52. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer l993;7l(ll):3640-6.
53. Karthaus M, Egerer G, Kullmann KH, Ritter J, Jurgens H. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998;17(7):501-4.
54. Pizzo PA. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here? J Antimicrob Chemother 2OO9;63 Suppl 1:i16-i17.
55. Klasteraky J. The chaoging face of febrile neotropenia-from monotherapy to moulds to mucositis. Why empirical therapy? J Antimicrob Chemother 2009;63 Suppl 1:i14-i15.
56. Leibovici L, Paul M, Poznanski O, Drucker M. Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41(5):1127-33.
57. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neotropenia. Int J Antimicrob Agents 2007;29(5):501-9.
58. Smith PF, Booker BM. Ogundele AB, Kelchin P. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis 2005;52(3):255-9.
59. Jaksic B, Martinelli G, Perez-Oteyza J. Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42(5):597-607.
60. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004;38(6):989-91.
61. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54(6):567-71.
62. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 2005;80(9):1215-6.
63. Bennett JW. Lewis JS, Ellis MW. Dalbavancin in the treatment of complicated skin and soft tissue infections: a review. Ther Clin Risk Manag 2008;4(1):31-40.
64. Sincak CA, Schmidt JM. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 2009;43(6):1107-14.
65. Stein RA, Goetz RM, Ganea GM. Ceftobiprole: a new beta-lactam antibiotic. Int J Clin Pract 2009;63(6):930-43.
66. El Solh A. Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin Pharmacother 2009;10(10):1675-86.
67. Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 2009;64(2):364-369.
68. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol 2009;4:25-33.
69. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009;33(6):515-9.
70. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52.
71. Ellis M, Bodey GP. Febrile neutropenia. Ann N Y Acad Sci 2008;1138:329-50.
72. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353(10):977-87.
73. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P. et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353(10):988-98.
74. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007;25(30):4821-8.
75. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142(12 Pt 1):979-95.
76. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59(1):5-22.